SyntheMed REPEL-CV Receives Russian Approval
SyntheMed announced that its REPEL-CV barrier has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery.
synthemed
SyntheMed Receives Endorsement, New Patent
REPEL-CV, a bioresorbable anti-adhesion barrier developed by biomaterials company SyntheMed, has received an endorsement from Kids with Heart.
SyntheMed Nominated for Frost & Sullivan Award
The Iselin, NJ-based company was recognized for its REPEL-CV Anti-Adhesion Barrier.
SyntheMed’s REPEL-CV Approved by Australian Regulators
REPEL-CV, an anti-adhesion barrier developed by biomaterials company SyntheMed, has received approval by the Australian Therapeutic Goods Administration for use in open-heart surgery.
State of the Art: Anti-Adhesion Barriers
Many patients are concerned about the external scars that form following surgical procedures, but a much greater risk can come from internal scarring. Adhesions are a type of post-surgical scar tissue that forms between two internal organs or surfaces that are normally separated.